Evidence of activation of the Toll-like receptor-4 proinflammatory pathway in patients with schizophrenia

Journal of Psychiatry and Neuroscience

Volumn 41, Issue 3, 2016, Pages E46-E55

  García Bueno, Borja ^a,b   Gassó, Patricia ^c,e   MacDowell, Karina S ^a,b   Callado, Luis F ^a,d   Mas, Sergi ^a,c,e   Bernardo, Miguel ^a,c,e   Lafuente, Amalia ^a,c,e   Meana, J Javier ^a,d   Leza, Juan C ^a,b  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^e INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; MYELOID DIFFERENTIATION FACTOR 88; NEUROLEPTIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TOLL LIKE RECEPTOR 4; MYD88 PROTEIN, HUMAN; TLR4 PROTEIN, HUMAN;

ADULT; ARTICLE; CADAVER; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENOTYPING TECHNIQUE; HUMAN; INNATE IMMUNITY; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; PREFRONTAL CORTEX; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SUICIDE; WESTERN BLOTTING; AGED; DRUG EFFECTS; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; RETROSPECTIVE STUDY;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; MYELOID DIFFERENTIATION FACTOR 88; NF-KAPPA B; POLYMORPHISM, SINGLE NUCLEOTIDE; PREFRONTAL CORTEX; RETROSPECTIVE STUDIES; RNA, MESSENGER; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4;

EID: 84964761434     PISSN: 11804882     EISSN: 14882434     Source Type: Journal    
DOI: 10.1503/jpn.150195     Document Type: Article

References (63)

1. Kirkpatrick B, Miller BJ. Inflammation and schizophrenia. Schizophr Bull 2013;39:1174-9.
2. Khandaker GM, Cousins L, Deakin J, et al. Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. Lancet Psychiatry 2015;2:258-70.
3. Lampron A, Elali A, Rivest S. Innate immunity in the CNS: redefining the relationship between the CNS and Its environment. Neuron 2013;78:214-32.
4. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 2001;1:135-45.
5. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006;124:783-801.
6. Hanke ML, Kielian T. Toll-like receptors in health and disease in the brain: mechanisms and therapeutic potential. Clin Sci (Lond) 2011;121:367-87.
7. Piccinini AM, Midwood KS. DAMPening inflammation by modulating TLR signalling. Mediators Inflamm 2010;pii:672395.
8. Takeuchi O, Akira S. Toll-like receptors: their physiological role and signal transduction system. Int Immunopharmacol 2001;1:625-35.
9. Shimazu R, Akashi S, Ogata H, et al. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med 1999;189:1777-82.
10. Madrigal JL, Garcia-Bueno B, Caso JR, et al. Stress-induced oxidative changes in brain. CNS Neurol Disord Drug Targets 2006; 5:561-8.
11. García-Bueno B, Caso JR, Leza JC. Stress as a neuroinflammatory condition in brain: damaging and protective mechanisms. Neurosci Biobehav Rev 2008;32:1136-51.
12. Gárate I, Garcia-Bueno B, Madrigal JL, et al. Stress-induced neuroinflammation: role of the Toll-like receptor-4 pathway. Biol Psychiatry 2013;73:32-43.
13. García-Bueno B, Bioque M, Mac-Dowell KS, et al. Pro-/anti-inflammatory dysregulation in patients with first episode of psychosis: toward an integrative inflammatory hypothesis of schizophrenia. Schizophr Bull 2014a;40:376-87.
14. García-Bueno B, Bioque M, MacDowell KS, et al. Pro-/antiinflammatory dysregulation in early psychosis: results from a 1-year follow-up study. Int J Neuropsychopharmacol 2014;18:pii: pyu037.
15. Martínez-Gras I, Pérez-Nievas BG, García-Bueno B, et al. The antiinflammatory prostaglandin 15d-PGJ2 and its nuclear receptor PPARgamma are decreased in schizophrenia. Schizophr Res 2011;128:15-22.
16. McKernan DP, Dennison U, Gaszner G et al. Enhanced peripheral toll-like receptor responses in psychosis: further evidence of a pro-inflammatory phenotype. Transl Psychiatry 2011;1:e36.
17. Müller N, Wagner JK, Krause D, et al. Impaired monocyte activation in schizophrenia. Psychiatry Res 2012;198:341-6.
18. Sommer IE, van Westrhenen R, Begemann MJ, et al. Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophr Bull 2014;40:181-91.
19. Avramopoulos D, Pearce BD, McGrath J, et al. Infection and inflammation in schizophrenia and bipolar disorder: a genome wide study for interactions with genetic variation. PLoS One 2015;10:e0116696.
20. Jia P, Wang L, Meltzer HY, et al. Common variants conferring risk of schizophrenia: a pathway analysis of GWAS data. Schizophr Res 2010;122:38-42.
21. Purcell SM, Wray NR, Stone JL, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009;460:748-52.
22. Hamshere ML, Walters JT, Smith R, et al. Genome-wide significant associations in schizophrenia to ITIH3/4, CACNA1C and SDCCAG8, and extensive replication of associations reported by the Schizophrenia PGC. Mol Psychiatry 2013;18:708-12.
23. Oliveira J, Busson M, Etain B, et al. Polymorphism of Toll-like receptor 4 gene in bipolar disorder. J Affect Disord 2014;152-154:395-402.
24. Okun E, Griffioen KJ, Mattson MP. Toll-like receptor signaling in neural plasticity and disease. Trends Neurosci 2011;34:269-81.
25. Venkatasubramanian G, Debnath M. The TRIPS (Toll-like receptors in immuno-inflammatory pathogenesis) hypothesis: a novel postulate to understand schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2013;44:301-11.
26. Severance EG, Gressitt KL, Stallings CR, et al. Discordant patterns of bacterial translocation markers and implications for innate immune imbalances in schizophrenia. Schizophr Res 2013;148:130-7.
27. MacDowell KS, Caso J, Martin-Hernandez D, et al. Paliperidone prevents brain Toll-like receptor 4 pathway activation and neuroinflammation in rat models of acute and chronic restraint stress. Int J Neuropsychopharmacol 2014;18:pii:pyu070.
28. Rajkowska G, Goldman-Rakic PS. Cytoarchitectonic definition of prefrontal areas in the normal human cortex: I. Remapping of areas 9 and 46 using quantitative criteria. Cereb Cortex 1995;5:307-22.
29. García-Sevilla JA, Alvaro-Bartolome M, Diez-Alarcia R, et al. Reduced platelet G protein-coupled receptor kinase 2 in major depressive disorder: antidepressant treatment-induced upregulation of GRK2 protein discriminates between responder and non-responder patients. Eur Neuropsychopharmacol 2010;20:721-30.
30. Schreiber E, Matthias P, Müller MM, et al. Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res 1989;17:6419.
31. Das NP, Ratty AK. Studies on the effects of the narcotic alkaloids, cocaine, morphine, and codeine on nonenzymatic lipid peroxidation in rat brain mitochondria. Biochem Med Metab Biol 1987;37:258-64.
32. First MB, Frances AJ, Pincus HA, et al. DSM-IV in progress. Changes in substance-related, schizophrenic, and other primarily adult disorders. Hosp Community Psychiatry 1994;45:18-20.
33. Lafuente A, Bernardo M, Mas S, et al. 141C Ins/Del polymorphism of the dopamine D2 receptor gene is associated with schizophrenia in a Spanish population. Psychiatr Genet 2008;18:122-7.
34. González JR, Armengol L, Sole X, et al. SNPassoc: an R package to perform whole genome association studies. Bioinformatics 2007; 23:644-5.
35. Moore JH, Gilbert JC, Tsai CT, et al. A flexible computational framework for detecting, characterizing, and interpreting statistical patterns of epistasis in genetic studies of human disease susceptibility. J Theor Biol 2006;241:252-61.
36. Young AM, Vetreno RP, Qin L, et al. Increased receptor for advanced glycation end product expression in the human alcoholic prefrontal cortex is linked to adolescent drinking. Front Psychiatry 2011;2:27.
37. Rao JS, Kim HW, Harry GJ, et al. Increased neuroinflammatory and arachidonic acid cascade markers, and reduced synaptic proteins, in the postmortem frontal cortex from schizophrenia patients. Schizophr Res 2013;147:24-31.
38. Malki K, Pain O, Tosto MG, et al. Identification of genes and gene pathways associated with major depressive disorder by integrative brain analysis of rat and human prefrontal cortex transcriptomes. Transl Psychiatry 2015;5:e519.
39. Young AM, Campbell E, Lynch S, et al. Aberrant NF-kappaB expression in autism spectrum condition: a mechanism for neuroinflammation. Front Psychiatry 2011;2:27.
40. Mistry M, Gillis J, Pavlidis P. Meta-analysis of gene coexpression networks in the post-mortem prefrontal cortex of patients with schizophrenia and unaffected controls. BMC Neurosci 2013;14:105.
41. Pae CU, Drago A, Kim JJ, et al. The impact of heat shock protein 70 gene variations on clinical presentation and outcome in schizophrenic inpatients. Neuropsychobiology 2009;59:135-41.
42. Dhandapani A, Narayanaswamy JC, Venkatasubramanian G. Adjuvant raloxifene treatment for negative symptoms of schizophrenia. Asian J Psychiatr 2013;6:254-5.
43. Reisinger S, Khan D, Kong E, et al. The poly(I:C)-induced maternal immune activation model in preclinical neuropsychiatric drug discovery. Pharmacol Ther 2015;149:213-26.
44. Abrahams VM, Bole-Aldo P, Kim YM, et al. Divergent trophoblast responses to bacterial products mediated by TLRs. J Immunol 2004;173:4286-96.
45. De MJ, Yaddanapudi K, Hornig M, et al. Induction of Toll-like receptor 3-mediated immunity during gestation inhibits cortical neurogenesis and causes behavioral disturbances. MBio 2010;1:pii: e00176-10.
46. Berk M, Williams LJ, Jacka FN, et al. So depression is an inflammatory disease, but where does the inflammation come from? BMC Med 2013;11:200.
47. Rosenberger K, Derkow K, Dembny P, et al. The impact of single and pairwise Toll-like receptor activation on neuroinflammation and neurodegeneration. J Neuroinflammation 2014;11:166.
48. Miller BJ, Buckley P, Seabolt W, et al. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 2011;70:663-71.
49. MacDowell KS, Garcia-Bueno B, Madrigal JL, et al. Risperidone normalizes increased inflammatory parameters and restores antiinflammatory pathways in a model of neuroinflammation. Int J Neuropsychopharmacol 2013;16:121-35.
50. Elmorsy E, Elzalabany LM, Elsheikha HM, et al. Adverse effects of antipsychotics on micro-vascular endothelial cells of the human blood-brain barrier. Brain Res 2014;1583:255-68.
51. Pillai A, Parikh V, Terry AV Jr, et al. Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J Psychiatr Res 2007;41:372-86.
52. Chen Z, Nakajima T, Inoue Y, et al. A single nucleotide polymorphism in the 3'-untranslated region of MyD88 gene is associated with Buerger disease but not with Takayasu arteritis in Japanese. J Hum Genet 2011;56:545-7.
53. Matsunaga K, Tahara T, Shiroeda H, et al. The *1244 A>G polymorphism of MyD88 (rs7744) is closely associated with susceptibility to ulcerative colitis. Mol Med Rep 2014;9:28-32.
54. Potter C, Cordell HJ, Barton A, et al. Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways. Ann Rheum Dis 2010;69:1315-20.
55. Burns K, Janssens S, Brissoni B, et al. Inhibition of interleukin 1 receptor/ Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4. J Exp Med 2003;197:263-8.
56. Lewis CM, Levinson DF, Wise LH, et al. Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: schizophrenia. Am J Hum Genet 2003;73:34-48.
57. He K, Wang Q, Chen J, et al. ITIH family genes confer risk to schizophrenia and major depressive disorder in the Han Chinese population. Prog Neuropsychopharmacol Biol Psychiatry 2014;51:34-8.
58. Ripke S, O'Dushlaine C, Chambert K, et al. Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat Genet 2013;45:1150-9.
59. Opal SM, Lim YP, Siryaporn E, et al. Longitudinal studies of inter-alpha inhibitor proteins in severely septic patients: a potential clinical marker and mediator of severe sepsis. Crit Care Med 2007; 35:387-92.
60. Paul-Samojedny M, Kowalczyk M, Suchanek R, et al. Functional polymorphism in the interleukin-6 and interleukin-10 genes in patients with paranoid schizophrenia-a case-control study. J Mol Neurosci 2010;42:112-9.
61. Xu M, He L. Convergent evidence shows a positive association of interleukin-1 gene complex locus with susceptibility to schizophrenia in the Caucasian population. Schizophr Res 2010;120:131-42.
62. Zakharyan R, Petrek M, Arakelyan A, et al. Interleukin-6 promoter polymorphism and plasma levels in patients with schizophrenia. Tissue Antigens 2012;80:136-42.
63. Kalmady SV, Venkatasubramanian G, Shivakumar V, et al. Relationship between interleukin-6 gene polymorphism and hippocampal volume in antipsychotic-naive schizophrenia: Evidence for differential susceptibility? PLoS One 2014;9:e96021.